Biocartis and A*STAR’s ETPL initiate development of breast cancer assay to guide therapy selection
Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company, today announced that it has extended its partnership with ETPL (the commercialization arm of A*STAR1) with a new five-year strategic partnership, focused on the development of molecular diagnostic assays for Biocartis’ Idylla™ platform, a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample.
The first assay selected for development under the partnership is a fully automated solid biopsy assay, aimed at supporting optimal therapy selection decisions for breast cancer patients.
Under the terms of the agreement, parties will co-invest in the development of jointly selected tests. For each selected test, Biocartis will be responsible for the commercialization of the tests under its own label, while ETPL will act as a development partner through Singapore’s Diagnostics Development (DxD) Hub.
Sidney Yee, CEO of the DxD Hub, and Executive Vice-President of ETPL said: “Over the years, Singapore’s investment in research and development has established a strong base of technological capabilities and produced a pipeline of cancer biomarkers. ETPL’s partnership with Biocartis is an excellent opportunity for us to accelerate the creation of diagnostics innovations that will serve the growing needs for early diagnosis of cancer, better patient monitoring and care, and lower health care costs.”
For the full press release, refer to link here.
1 On 17 July 2015, Biocartis signed a partnership agreement with ETPL